J Gen Virol Try Microbiology Online
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published as JGV in Press, 10.1099/vir.0.009308-0 on March 4, 2009 J Gen Virol 90 (2009), 1119-1123; DOI 10.1099/vir.0.009308-0

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
vir.0.009308-0v1
90/5/1119    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miao, C.
Right arrow Articles by Haynes, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miao, C.
Right arrow Articles by Haynes, L. M.
Agricola
Right arrow Articles by Miao, C.
Right arrow Articles by Haynes, L. M.

Short Communication

Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice

Congrong Miao1, Gertrud U. Radu1, Hayat Caidi1, Ralph A. Tripp2, Larry J. Anderson1 and Lia M. Haynes1

1 National Centers for Immunization and Respiratory Disease, Division of Viral Diseases, Respiratory and Gastroenteritis Viruses Laboratory Branch, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road NE, Atlanta, GA 30333, USA
2 College of Veterinary Medicine, Department of Infectious Disease, University of Georgia, Athens, GA 30602, USA

Correspondence
Lia M. Haynes
loh5{at}cdc.gov

Therapeutic treatment with a non-neutralizing monoclonal antibody (mAb) (131-2G) specific to respiratory syncytial virus (RSV) G glycoprotein mediates virus clearance and decreases leukocyte trafficking and interferon gamma (IFN-{gamma}) production in the lungs of RSV-infected mice. Its F(ab')2 component only mediates decreased leukocyte trafficking and IFN-{gamma} production without reducing virus replication. Thus, this mAb has two independent actions that could facilitate treatment and/or prevention of RSV infection by reducing both virus replication and virus-induced pulmonary inflammation.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
E. J. Collarini, F. E.-H. Lee, O. Foord, M. Park, G. Sperinde, H. Wu, W. D. Harriman, S. F. Carroll, S. L. Ellsworth, L. J. Anderson, et al.
Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected Patients
J. Immunol., November 15, 2009; 183(10): 6338 - 6345.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL
J MED MICROBIOL ALL SGM JOURNALS
Copyright © 2009 by the Society for General Microbiology.